Clinical Trial

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

Name: ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy — clinical trial record (NCT07218887)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DCMRestore

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.

Protocol Amendment History 1 change

notable Trial sites expanded: 7 -> 10 locations 2026-06-16

Trial Details

NCT Number	NCT07218887
Lead Sponsor	Alexion Pharmaceuticals, Inc.
Conditions	BAG3 Mutation Associated Dilated Cardiomyopathy
Enrollment	6 participants
Start Date	2025-10-24
Primary Completion	2032-01-27 (estimated)
Study Completion	2032-01-27 (estimated)
Updated on ClinicalTrials.gov	2026-06-15